Literature DB >> 17157273

Expression and localization of Cayman ataxia-related protein, Caytaxin, is regulated in a developmental- and spatial-dependent manner.

Yoshika Hayakawa1, Masanori Itoh, Aiko Yamada, Teruhiko Mitsuda, Toshiyuki Nakagawa.   

Abstract

Mutation of the gene encoding Caytaxin causes human Cayman ataxia by interfering with normal splicing and, in mutant rodents, by reducing normal transcription, which leads to ataxia, dystonia, and mental retardation: These observations suggest that Caytaxin may be crucial for higher brain functions such as motor learning. We generated antibodies against mouse Caytaxin. Interestingly, we found that the expression of Caytaxin is regulated during brain development while quantitative real time RT-PCR indicated that the mRNA level did not change between postnatal days 7 (P7) and P14 in the cerebellum and hippocampus, implying that the expression of Caytaxin may be controlled by a post-transcriptional mechanism. Immunostaining analyses demonstrated that Caytaxin was localized in many brain areas including the cerebellum and hippocampus. Furthermore, Caytaxin was localized to the presynaptic cytosol by the subcellular fractionation of mouse brain and an observation that was confirmed by co-localization studies with synapsin I and VGLUT1. The above data, disease phenotypes, and mutant animals suggest that Caytaxin may be essential for synaptic function. Thus, identifying the role of Caytaxin in synapse maturation may lead to the development of therapeutic interventions for cerebellar ataxia as well as mental disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17157273     DOI: 10.1016/j.brainres.2006.10.068

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

1.  Cayman ataxia-related protein is a presynapse-specific caspase-3 substrate.

Authors:  Masanori Itoh; Shimo Li; Kazunori Ohta; Aiko Yamada; Yoshika Hayakawa-Yano; Masashi Ueda; Yoko Hida; Yoshihiro Suzuki; Eri Ohta; Akihito Mizuno; Yoshiko Banno; Toshiyuki Nakagawa
Journal:  Neurochem Res       Date:  2011-03-03       Impact factor: 3.996

2.  Mammalian diseases of phosphatidylinositol transfer proteins and their homologs.

Authors:  Aaron H Nile; Vytas A Bankaitis; Aby Grabon
Journal:  Clin Lipidol       Date:  2010-12-01

3.  Neural expression of the transcription factor THAP1 during development in rat.

Authors:  Y Zhao; J Xiao; S Gong; J A Clara; M S Ledoux
Journal:  Neuroscience       Date:  2012-12-05       Impact factor: 3.590

4.  Vocal development in dystonic rats.

Authors:  Tobias Riede; Yu Zhao; Mark S LeDoux
Journal:  Physiol Rep       Date:  2015-04

5.  Genome-Wide Association Study and Subsequent Exclusion of ATCAY as a Candidate Gene Involved in Equine Neuroaxonal Dystrophy Using Two Animal Models.

Authors:  Erin N Hales; Christina Esparza; Sichong Peng; Anna R Dahlgren; Janel M Peterson; Andrew D Miller; Carrie J Finno
Journal:  Genes (Basel)       Date:  2020-01-10       Impact factor: 4.096

6.  A combination of multiple autoantibodies is associated with the risk of Alzheimer's disease and cognitive impairment.

Authors:  Sung-Mi Shim; Young Ho Koh; Jong-Hoon Kim; Jae-Pil Jeon
Journal:  Sci Rep       Date:  2022-01-25       Impact factor: 4.379

7.  Expression of Caytaxin protein in Cayman Ataxia mouse models correlates with phenotype severity.

Authors:  Kristine M Sikora; LaGina M Nosavanh; Prameela Kantheti; Margit Burmeister; Michael Hortsch
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

8.  Nerve growth factor stimulates interaction of Cayman ataxia protein BNIP-H/Caytaxin with peptidyl-prolyl isomerase Pin1 in differentiating neurons.

Authors:  Jan Paul Buschdorf; Li Li Chew; Unice Jim Kim Soh; Yih-Cherng Liou; Boon Chuan Low
Journal:  PLoS One       Date:  2008-07-16       Impact factor: 3.240

Review 9.  DAPK1 Signaling Pathways in Stroke: from Mechanisms to Therapies.

Authors:  Shan Wang; Xiangde Shi; Hao Li; Pei Pang; Lei Pei; Huiyong Shen; Youming Lu
Journal:  Mol Neurobiol       Date:  2016-07-22       Impact factor: 5.590

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.